April 2024 in “Journal of clinical medicine” Effective treatment guidelines for frontal fibrosing alopecia are still unclear.
Frontal fibrosing alopecia can be managed with personalized combination therapies, but no cure exists yet.
46 citations
,
April 2020 in “Drugs” Emerging therapies like JAK inhibitors show promise for hair regrowth in alopecia areata.
December 2024 in “Dermatological Reviews” New treatments for Alopecia Areata, like JAK inhibitors, are effective, and future research is exploring advanced therapies.
11 citations
,
January 2022 in “Journal der Deutschen Dermatologischen Gesellschaft” Alopecia areata is a chronic condition causing hair loss, with new treatments targeting the immune system showing promise.
5 citations
,
April 2025 in “Journal of the European Academy of Dermatology and Venereology” Control inflammation and prevent further hair loss in folliculitis decalvans using medications and therapies.
6 citations
,
April 2021 in “Frontiers in Immunology” A patient with lupus and long-term hair loss saw significant hair regrowth after using the drug tofacitinib.
October 2023 in “bioRxiv (Cold Spring Harbor Laboratory)” A protein called EGFR protects hair follicle stem cells, and when it's disrupted, hair follicles can be damaged, but blocking certain pathways can restore hair growth.
5 citations
,
June 2019 in “British Journal of Dermatology” Tofacitinib was more effective than apremilast in treating hair loss in a mouse model of alopecia areata.
4 citations
,
July 2025 in “Frontiers in Immunology” Early intervention with JAK inhibitors may prevent alopecia areata progression.
3 citations
,
February 2024 in “Journal of the American Academy of Dermatology” Topical tofacitinib cream may help treat certain hair loss conditions with fewer risks.
3 citations
,
August 2021 in “Veterinary dermatology” New treatments for hair loss are emerging as we better understand hair growth and its genetic causes.
49 citations
,
March 2017 in “Journal of the American Academy of Dermatology” Tofacitinib caused significant hair regrowth in adolescents with alopecia universalis who didn't respond to other treatments.
The authors suggest that 5-α-reductase inhibitors, like dutasteride, are effective in treating frontal fibrosing alopecia and should be the first-line treatment, with other options for severe cases. They also recommend further research on Janus kinase inhibitors.
April 2024 in “Expert opinion on investigational drugs” JAK inhibitors are safe and effective for treating moderate-to-severe alopecia areata.
February 2026 in “Indian Journal of Skin Allergy” Ruxolitinib cream effectively treats skin conditions like atopic dermatitis and vitiligo with minimal side effects.
March 2025 in “Meditsinskiy sovet = Medical Council” Dupilumab and oral JAK inhibitors are effective for treating alopecia areata with atopic diseases.
January 2024 in “Dermatologic therapy” Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.
October 2023 in “Frontiers in medicine” Comprehensive screening for infections is crucial before starting JAK inhibitors in alopecia areata patients.
March 2024 in “Dermatology and therapy” AA patients with comorbid conditions face more severe hair loss and need specific treatments.
277 citations
,
December 2019 in “Frontiers in Immunology” JAK inhibitors show promise for treating skin disorders like alopecia, eczema, and psoriasis.
3 citations
,
July 2024 in “Archives of Dermatological Research” Oral ritlecitinib and baricitinib are promising treatments for severe alopecia areata due to their balance of effectiveness and safety.
November 2025 in “Journal of Investigative Dermatology” Combining MMP-9 and JAK inhibitors can effectively prevent skin depigmentation in vitiligo.
20 citations
,
January 2018 in “Expert opinion on emerging drugs” JAK inhibitors may soon be a safe and effective treatment for alopecia areata.
December 2025 in “ADMET & DMPK” Personalized treatments for hair loss focus on specific genetic and biological pathways.
September 2023 in “JAAD case reports” A man developed oral hairy leukoplakia while on baricitinib, a medication for alopecia and arthritis, and doctors should watch for such side effects.
August 2024 in “New Zealand Medical Student Journal” JAK inhibitors show promise for treating skin diseases effectively and safely.
January 2026 in “Journal of Clinical Medicine” Janus kinase inhibitors reduce inflammation markers in severe alopecia areata patients.
489 citations
,
November 2021 in “Signal Transduction and Targeted Therapy” The JAK/STAT pathway is important in cell processes and disease, and JAK inhibitors are promising for treating related conditions.
January 2026 in “Skin Health and Disease” Irish dermatologists use JAK inhibitors for alopecia areata but want standardized treatment guidelines.